NEWPORT NEWS, Va., June 9 /PRNewswire/ -- A group of surgeons from Legacy Good Samaritan Hospital (Portland, Oregon) have found Breast-Specific Gamma Imaging (BSGI) has a significant value in the pre-operative assessment for the extent of breast cancer in patients with known diagnosis. The findings were presented at The Society of Black Academic Surgeons Annual meeting held in Cleveland, Ohio.
BSGI is a molecular breast imaging technique used for the early detection of breast cancer and in the differentiation of malignant and benign tumors. It relies on advanced gamma imaging technology and mammographic positioning to optimize results. For this study BSGI was conducted with a commercially available high-resolution gamma camera, the Dilon 6800.
The study evaluated 138 patients with a cancer diagnosis. In this group, additional disease was found in a total of 11 percent of patients. Six percent were in the same breast and 5 percent were in the opposite breast. This finding is very similar to that of an MRI study conducted by Bilimoria from Northwestern University; however, BSGI provided a significantly lower false positive rate of 7 percent compared to 78 percent with the MRI study.
Member of the Legacy Good Samaritan Hospital group of surgeons, Dr. M. Zhou, concluded that BSGI parallels MRI in sensitivity in the preoperative setting, demonstrates better specificity than MRI, and is less expensive than MRI.
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.
M. Zhou MD, N. Johnson MD, S. Gruner MD, G.W. Ecklund MD, P. Meunier MD, S. Bryn RN, G. Green MD. Clinical Utility of Breast Specific Gamma Imaging For Evaluating Disease Extent in the Newly Diagnosed Breast Cancer Patient. SBAS 18th Annual Scientific Session, Cleveland, OH, April 18, 2008.
|SOURCE Dilon Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved